Summary
The progression of diabetic nephropathy can be positively influenced by maintaining a low blood pressure level. This has been shown in studies with conventional antihypertensive treatment as well as with ACE inhibitors. Whether the latter group of drugs is more effective remains to be proven and was the aim of our study. In a prospective randomized study we compared the effects of ACE inhibition and β-blockade on retarding progression of renal function in IDDM patients with an early stage of overt diabetic nephropathy. Twenty-nine patients were studied for 2 years, 15 were randomized for treatment with captopril and 14 for atenolol. Every 6 weeks blood pressure and urinary albumin and total protein excretion were measured. GFR was measured every 6 months as 51Cr-EDTA clearance. Baseline values for blood pressure, renal function and albuminuria were identical in the two groups. The effect of both drugs on blood pressure was not significantly different. In the captopril-treated patients MAP before and after 2 years was 110±3 (SEM) and 100±2 mm Hg, respectively and in the atenolol-treated patients 105±2 vs 101±2 mm Hg. Both drugs reduced albuminuria and total proteinuria to the same extent. With captopril albuminuria decreased from 1549 (989–2399) to 851 (537–1380) mg/24 h and proteinuria from 2.5 (1.6–3.8) to 1.2 (0.8–1.8) g/24 h. With atenolol albuminuria decreased from 933 (603–1445) to 676 (437–1047) mg/ 24 h and proteinuria from 1.5 (1.0–2.4) to 0.9 (0.6–1.5) g/24 h. The rate of decline of GFR was similar with both treatments, on captopril −4.9±2.1 and on atenolol −3.7±1.6 ml · min−1· year−1. No major side effects with either drug were observed. We conclude that, in this 2-year study, captopril and atenolol are equally effective in retarding progression of diabetic nephropathy.
Article PDF
Similar content being viewed by others
Abbreviations
- IDDM:
-
insulin-dependent diabetes mellitus
- ACE:
-
angiotensin converting enzyme
- ECC:
-
endogenous creatinine clearance
- MAP:
-
mean arterial pressure
- GFR:
-
glomerular filtration rate
References
Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–688
Parving H-H, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175–1179
Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375–380
Taguma Y, Kitamoto Y, Futaki G et al. (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620
Elving LD, Wetzels JFM, De Nobel E, Hoitsma AJ, Berden JHM (1992) Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 20: 559–563
Rijk MCM, Van Lier HJJ, Van Tongeren JHM (1992) Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 87: 438–442
Elving LD, Bakkeren JAJM, Jansen MJH, De Kat Angelino CM, De Nobel E, Van Munster PJJ (1989) Screening for microalbuminuria in patients with diabetes mellitus: frozen storage of urine samples decreases their albumin content. Clin Chem 35: 308–310
Drayer JIM, Benraad ThJ (1975) The reliability of the measurement of plasma renin activity by radioimmunoassay. Clin Chim Acta 61: 309–324
Bröchner-Mortensen J, Rödbro P (1976) Selection of a routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36: 35–43
Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH (1981) A distribution-free test for tumor-growth curve analysis with application to an animal tumor immunotherapy experiment. Biometrics 37: 383–390
Kamper A-L, Nielsen OJ (1990) Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50: 611–618
Williams PS, Fass G, Bone JM (1988) Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 252: 343–354
Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384–394
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D (1987) Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 32: 78–83
Parving H-H, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 297: 1086–1091
Kloke HJ, Wetzels JFM, van Hamersvelt HW, Koene RAP, Kleinbloesem CH, Huysmans FThM (1990) Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 16: 924–930
Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effects of enalapril in diabetic nephropathy. BMJ 304: 339–343
Erley CM, Harre U, Krämer BK, Risler T (1992) Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor. Kidney Int 41: 1297–1303
Stornello M, Valvo EV, Scapellato L (1992) Persistent albuminuria in normotensive non-insulin-dependent (type 2) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci 82: 19–23
Kloke HJ, Wetzels JFM, Huysmans FThM, van Hamersvelt HW, Koene RAP (1993) Angiotensin converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in reducing proteinuria in patients with glomerulonephritis. Nephrol Dial Transplant 8: 808–813
Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE (1991) Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 303: 821–824
Weidmann P, Boehlen LM, de Courten M (1993) Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8: 582–584
Mogensen CE, Hansen KW, Østerby R, Damsgaard EM (1992) Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 15: 1192–1204
Mogensen CE (1976) Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36: 383–388
Parving H-H, Rossing P, Hommel E, Smidt UM (1992) Renal protective effects of captopril and metoprolol in diabetic nephropathy. Diabetologia 35 [Suppl 1]: A148 (Abstract)
Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 293: 471–474
Parving H-H, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 299: 533–536
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elving, L.D., Wetzels, J.F.M., van Lier, H.J.J. et al. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 37, 604–609 (1994). https://doi.org/10.1007/BF00403380
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403380